305 related articles for article (PubMed ID: 21617789)
21. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
22. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
23. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
24. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Nagykálnai T
Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
[TBL] [Abstract][Full Text] [Related]
25. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
26. Appraising adjuvant aromatase inhibitor therapy.
Perez EA
Oncologist; 2006; 11(10):1058-69. PubMed ID: 17110624
[TBL] [Abstract][Full Text] [Related]
27. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
28. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Menas P; Merkel D; Hui W; Lawton J; Harper A; Carro G
J Oncol Pharm Pract; 2012 Dec; 18(4):387-93. PubMed ID: 22277833
[TBL] [Abstract][Full Text] [Related]
29. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
30. The discovery and mechanism of action of letrozole.
Bhatnagar AS
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):7-17. PubMed ID: 17912633
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Henry NL; Giles JT; Stearns V
Oncology (Williston Park); 2008 Nov; 22(12):1401-8. PubMed ID: 19086600
[TBL] [Abstract][Full Text] [Related]
32. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
33. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Higgins MJ; Liedke PE; Goss PE
Crit Rev Oncol Hematol; 2013 Apr; 86(1):23-32. PubMed ID: 23116626
[TBL] [Abstract][Full Text] [Related]
34. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti S
Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
[No Abstract] [Full Text] [Related]
35. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
36. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
[TBL] [Abstract][Full Text] [Related]
37. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
Morales L; Pans S; Verschueren K; Van Calster B; Paridaens R; Westhovens R; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
J Clin Oncol; 2008 Jul; 26(19):3147-52. PubMed ID: 18474874
[TBL] [Abstract][Full Text] [Related]
38. Adherence rates and correlates in long-term hormonal therapy.
Dunn J; Gotay C
Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
[TBL] [Abstract][Full Text] [Related]
39. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
40. Tolerance of adjuvant letrozole outside of clinical trials.
Fontaine C; Meulemans A; Huizing M; Collen C; Kaufman L; De Mey J; Bourgain C; Verfaillie G; Lamote J; Sacre R; Schallier D; Neyns B; Vermorken J; De Grève J
Breast; 2008 Aug; 17(4):376-81. PubMed ID: 18455395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
